Published in AIDS on April 24, 2010
Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: a model-based analysis. Sci Transl Med (2013) 2.28
Tuberculosis screening in high human immunodeficiency virus prevalence settings: turning promise into reality. Int J Tuberc Lung Dis (2013) 1.03
Efficacy of a six-month versus a 36-month regimen for prevention of tuberculosis in HIV-infected persons in India: a randomized clinical trial. PLoS One (2012) 0.96
Performance of symptom-based tuberculosis screening among people living with HIV: not as great as hoped. AIDS (2014) 0.93
Diagnosing latent tuberculosis in high-risk individuals: rising to the challenge in high-burden areas. J Infect Dis (2011) 0.87
Latent and subclinical tuberculosis in HIV infected patients: a cross-sectional study. BMC Infect Dis (2012) 0.84
Intensive case finding and isoniazid preventative therapy in HIV infected individuals in Africa: economic model and value of information analysis. PLoS One (2012) 0.82
Rifampicin resistance after treatment for latent tuberculous infection: a systematic review and meta-analysis. Int J Tuberc Lung Dis (2016) 0.81
Treatment of latent tuberculosis infection in HIV: shorter or longer? Curr HIV/AIDS Rep (2012) 0.80
"It's about my life": facilitators of and barriers to isoniazid preventive therapy completion among people living with HIV in rural South Africa. AIDS Care (2017) 0.79
Risk of Disease After Isoniazid Preventive Therapy for Mycobacterium tuberculosis Exposure in Young HIV-uninfected Children. Pediatr Infect Dis J (2015) 0.78
An evaluation of factors associated with taking and responding positive to the tuberculin skin test in individuals with HIV/AIDS. BMC Public Health (2011) 0.78
Implementation of Tuberculosis Intensive Case Finding, Isoniazid Preventive Therapy, and Infection Control ("Three I's") and HIV-Tuberculosis Service Integration in Lower Income Countries. PLoS One (2016) 0.78
Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons. World J Virol (2015) 0.76
Barriers in the implementation of isoniazid preventive therapy for people living with HIV in Northern Ethiopia: a mixed quantitative and qualitative study. BMC Public Health (2016) 0.75
Implementation and evaluation of an isoniazid preventive therapy pilot program among HIV-infected patients in Vietnam, 2008-2010. Trans R Soc Trop Med Hyg (2015) 0.75
Mortality after fluid bolus in African children with severe infection. N Engl J Med (2011) 10.99
HIV decline associated with behavior change in eastern Zimbabwe. Science (2006) 6.98
HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet (2009) 6.96
Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet (2006) 5.98
Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med (2006) 5.73
Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS (2008) 5.26
Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med (2011) 4.29
A trial of mass isoniazid preventive therapy for tuberculosis control. N Engl J Med (2014) 4.07
Achieving the health Millennium Development Goals for South Africa: challenges and priorities. Lancet (2009) 3.35
Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am J Respir Crit Care Med (2004) 3.26
Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS (2007) 3.19
Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis (2002) 2.60
Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme. AIDS (2010) 2.60
Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006. Clin Infect Dis (2008) 2.42
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med (2014) 2.42
Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis (2010) 2.38
Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis (2008) 2.32
Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis (2006) 2.29
Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis (2009) 2.25
Effectiveness of a strategy to improve adherence to tuberculosis treatment in a resource-poor setting: a cluster randomized controlled trial. JAMA (2007) 2.13
Use of traditional medicine by HIV-infected individuals in South Africa in the era of antiretroviral therapy. Psychol Health Med (2007) 2.08
HIV infection does not affect active case finding of tuberculosis in South African gold miners. Am J Respir Crit Care Med (2009) 2.07
Provider-initiated symptom screening for tuberculosis in Zimbabwe: diagnostic value and the effect of HIV status. Bull World Health Organ (2010) 2.03
"That is why I stopped the ART": patients' & providers' perspectives on barriers to and enablers of HIV treatment adherence in a South African workplace programme. BMC Public Health (2008) 1.96
Linking women who test HIV-positive in pregnancy-related services to long-term HIV care and treatment services: a systematic review. Trop Med Int Health (2012) 1.78
The natural history of HIV-1 and HIV-2 infections in adults in Africa: a literature review. Bull World Health Organ (2004) 1.76
Eosinophilia in returning travellers and migrants from the tropics: UK recommendations for investigation and initial management. J Infect (2010) 1.73
Integrating tuberculosis and HIV services in low- and middle-income countries: a systematic review. Trop Med Int Health (2012) 1.66
HIV/AIDS treatment and HIV vaccines for Africa. Lancet (2002) 1.58
Age at first sex and HIV infection in rural Zimbabwe. Stud Fam Plann (2007) 1.53
Performance characteristics of the Cepheid Xpert MTB/RIF test in a tuberculosis prevalence survey. PLoS One (2012) 1.53
Evaluation of a workplace HIV treatment programme in South Africa. AIDS (2007) 1.52
Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy? AIDS (2003) 1.51
Barriers to implementation of isoniazid preventive therapy in HIV clinics: a qualitative study. AIDS (2010) 1.50
Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. J Infect Dis (2007) 1.49
Early risk assessment for viral haemorrhagic fever: experience at the Hospital for Tropical Diseases, London, UK. J Infect (2006) 1.47
Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. PLoS Med (2012) 1.44
Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort study. BMC Infect Dis (2008) 1.41
Diagnostic accuracy of a urine lipoarabinomannan enzyme-linked immunosorbent assay for screening ambulatory HIV-infected persons for tuberculosis. J Acquir Immune Defic Syndr (2011) 1.41
Malaria in camps for internally-displaced persons in Uganda: evaluation of an insecticide-treated bednet distribution programme. Trans R Soc Trop Med Hyg (2004) 1.40
Undiagnosed tuberculosis among HIV clinic attendees: association with antiretroviral therapy and implications for intensified case finding, isoniazid preventive therapy, and infection control. J Acquir Immune Defic Syndr (2012) 1.39
Stable incidence rates of tuberculosis (TB) among human immunodeficiency virus (HIV)-negative South African gold miners during a decade of epidemic HIV-associated TB. J Infect Dis (2003) 1.36
Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events. AIDS (2008) 1.32
Patient attrition between diagnosis with HIV in pregnancy-related services and long-term HIV care and treatment services in Kenya: a retrospective study. J Acquir Immune Defic Syndr (2012) 1.31
Low haemoglobin predicts early mortality among adults starting antiretroviral therapy in an HIV care programme in South Africa: a cohort study. BMC Public Health (2010) 1.30
Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study. PLoS One (2013) 1.29
Comparison of household-survey estimates with projections of mortality and orphan numbers in sub-Saharan Africa in the era of HIV/AIDS. Popul Stud (Camb) (2004) 1.23
Changing predictors of mortality over time from cART start: implications for care. J Acquir Immune Defic Syndr (2011) 1.22
Assessing the performance of overseas tuberculosis screening programs: a study among US-bound immigrants in Vietnam. Arch Intern Med (2006) 1.22
Mortality associated with delays between clinic entry and ART initiation in resource-limited settings: results of a transition-state model. J Acquir Immune Defic Syndr (2013) 1.18
Tuberculosis and HIV coinfection: current state of knowledge and research priorities. J Infect Dis (2007) 1.18
Does tuberculosis increase HIV load? J Infect Dis (2004) 1.18
Early loss to follow-up of recently diagnosed HIV-infected adults from routine pre-ART care in a rural district hospital in Kenya: a cohort study. Trop Med Int Health (2011) 1.17
Thibela TB: design and methods of a cluster randomised trial of the effect of community-wide isoniazid preventive therapy on tuberculosis amongst gold miners in South Africa. Contemp Clin Trials (2010) 1.16
Adverse events with isoniazid preventive therapy: experience from a large trial. AIDS (2010) 1.15
Outcomes following virological failure and predictors of switching to second-line antiretroviral therapy in a South African treatment program. J Acquir Immune Defic Syndr (2012) 1.13
Second-line antiretroviral therapy in a workplace and community-based treatment programme in South Africa: determinants of virological outcome. PLoS One (2012) 1.13